Quick Overview: This presentation discussed the ANDA landscape for topical products applied to the skin and identified challenges associated ... This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... The first of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference.
Agdd 2024 D2s10 1 Analysis - Detailed Overview & Context
This presentation discussed the ANDA landscape for topical products applied to the skin and identified challenges associated ... This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... The first of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. dissolution issues and examined OGD's bioequivalence evaluation based on the totality of evidence for this case. The session ... This presentation recognized the significant challenges associated with conducting comparative clinical endpoint (CCEP) ... The first of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference.
This presentation addressed safety concern thresholds for extractables and leachables in ANDA submissions and covered ... This presentation examined In Vitro Release Testing (IVRT) for drug products containing nanomaterials, with a specific focus on ... FDA experts demonstrate the FDA's Generic Drug User Fee Amendments (GDUFA) Science and Research Program's ... This presentation discussed the complexity of generic oligonucleotides and RLD-equivalence considerations, while reviewing key ... This presentation identified FDA resources to assist with the Bio-IND process and provided an This presentation described critical considerations for formulation development when a test product fails to meet the "no significant ...
This presentation discussed in silico methodologies for topical products applied to the skin, with particular focus on dermal ... This presentation provided key principles for comparative The second of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. The second of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. This presentation provided an overview of the model-integrated evidence (MIE) industry meeting pilot program and shared what ... This presentation identified recent product-specific guidance (PSG) documents that include detailed language regarding the use ...
Closing remarks from day one of the Advancing Generic Drug Development Conference delivered by Dr. Sau (Larry) Lee.
